SLC7A11 and cancer: Notably, therapies targeting disulphide stress prevention such as N‐acetyl cysteine and penicillamine (which convert intracellular cysteine to cysteine through disulphide exchange), or disulphide‐reducing agents tris(2‐carboxyethyl)phosphine and 2‐mercaptoethanol (which reduce extracellular cysteine to cysteine, enabling cells to acquire intracellular cysteine independently of SLC7A11), restore NADPH levels, prevent abnormal accumulation of intracellular disulphide molecules, and inhibit cell death in glucose‐starved SLC7A11‐high cancer cells.18